Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic

International Journal of Infectious Diseases(2021)10.1016/j.ijid.2021.02.067Source: DataRank Database

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic is a research paper published in International Journal of Infectious Diseases (2021). On theSindex it has a DataRank of 0. It has been cited 58 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access58 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 2.90)OA: goldTopics (34)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

M. Vjecha ORCID,Adam Zumla,Jessica Galvin ORCID,Giovanni Battista Migliori ORCID,Alimuddin Zumla ORCID

Live enrichment

PubMed:33713815 PMC:PMC7944856 OpenAlex:https://openalex.org/W3134334017

National Institute for Health Research (NIHR)

Grant: NF-SI-0616-10016

FWCI

2.90

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttp://www.ijidonline.com/article/S1201971221001533/pdf

publisherhttp://www.ijidonline.com/article/S1201971221001533/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1201971221001533?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1201971221001533?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ijid.2021.02.067

Fields of Study

Tuberculosis Research and EpidemiologyPneumocystis jirovecii pneumonia detection and treatmentPneumonia and Respiratory Infections

MeSH Terms

COVID-19SARS-CoV-2Clinical ProtocolsHumansTuberculosis, Multidrug-ResistantPandemics

Keywords

MedicineBedaquilinePandemicRegimenIntensive care medicineTuberculosisAnticipation (artificial intelligence)Coronavirus disease 2019 (COVID-19)DrugDrug resistanceCulture conversionInternal medicineDiseasePharmacologyPulmonary tuberculosisInfectious disease (medical specialty)PathologyMycobacterium tuberculosisdrug discoveryClinical TrialsMdr-tbpipelineNew DrugsNew Treatment RegimensCovid-19

Sustainable Development Goals

SDG 0: Good health and well-being

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic

FAIR Checklist

Authors (6)

Funding (1 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)